Spherix Global Insights

February 15, 2019

RealTime Dynamix™: Hyperkalemia US Q1 2019 Spotlight

RealTime Dynamix™: Hyperkalemia US Q1 2019 Spotlight

https://www.spherixglobalinsights.com/wp-content/uploads/2019/06/RTD-HK-Q1-2019.pngDownload Report Spotlight

Last week the FDA approved two products, Pfizer’s Retacrit and AstraZeneca’s Lokelma, both of which encountered lengthy regulatory delays. Retacrit is the first biosimilar ESA to enter the US market and will compete with Amgen’s Epogen and Aranesp and Roche’s Mircera. Lokelma (sodium zirconium cyclosilicate) is an oral potassium binder that will compete with Relypsa’s Veltassa which has been unchallenged in the market since its US approval in October 2015.

Reports based on survey responses of approximately 100 nephrologists and 100 cardiologists each quarter, RealTime Dynamix™: Hyperkalemia (Nephrology Perspective) and (Cardiology Perspective) provides a detailed and timely look at how the hyperkalemia market is evolving with quarterly updates of treatment patterns, comparative industry contact rates, key launch metrics for Veltassa and Lokelma, and awareness of products in development. See complimentary highlights below.

Contact info@spherixglobalinsights.com for more information about the highlighted report or to see if your company has access to either report series highlighted.


All company, brand or product names and logos in this document are trademarks of their respective holders.